Cassava Sciences Files 8-K on Shareholder Votes and Financials

Ticker: FLNA · Form: 8-K · Filed: May 13, 2024 · CIK: 1069530

Cassava Sciences INC 8-K Filing Summary
FieldDetail
CompanyCassava Sciences INC (FLNA)
Form Type8-K
Filed DateMay 13, 2024
Risk Levellow
Pages2
Reading Time3 min
Key Dollar Amounts$0.001
Sentimentneutral

Sentiment: neutral

Topics: corporate-governance, financials, filing

Related Tickers: SAVA

TL;DR

Cassava Sciences filed an 8-K on May 9th covering shareholder votes and financials.

AI Summary

Cassava Sciences, Inc. filed an 8-K on May 13, 2024, reporting on matters submitted to a vote of security holders and financial statements as of May 9, 2024. The filing details the company's corporate structure and its status as a pharmaceutical preparations company.

Why It Matters

This filing provides an update on important corporate actions and financial reporting for Cassava Sciences, which is relevant for investors tracking the company's governance and financial health.

Risk Assessment

Risk Level: low — This filing is a routine corporate disclosure and does not contain new material events that would inherently increase risk.

Key Players & Entities

FAQ

What specific matters were submitted to a vote of security holders?

The filing indicates that matters were submitted to a vote of security holders, but the specific details of these matters are not elaborated upon in the provided text.

What is the primary business of Cassava Sciences, Inc.?

Cassava Sciences, Inc. is classified under the Standard Industrial Classification code 2834, which pertains to Pharmaceutical Preparations.

When was the earliest event reported in this 8-K filing?

The earliest event reported in this 8-K filing occurred on May 9, 2024.

What is the company's state of incorporation?

The company is incorporated in Delaware.

What is the company's IRS Employer Identification Number?

The company's IRS Employer Identification Number is 91-1911336.

Filing Stats: 707 words · 3 min read · ~2 pages · Grade level 10.9 · Accepted 2024-05-13 16:30:55

Key Financial Figures

Filing Documents

07 Submission of Matters to a Vote of Security Holders

Item 5.07 Submission of Matters to a Vote of Security Holders. The 2024 Annual Meeting of Stockholders (the "Annual Meeting") of Cassava Sciences, Inc. (the "Company") was held at approximately 10 a.m. Central Time on May 9, 2024, pursuant to the Notice of Annual Meeting of Stockholders dated March 26, 2024 and duly delivered to all Company stockholders of record as of March 19, 2024. Of the 43,246,878 shares of the Company's common stock entitled to vote at the Annual Meeting, 26,979,468 shares, or approximately 62%, were represented at the Annual Meeting virtually or by proxy, constituting a quorum. At the Annual Meeting, the Company's stockholders voted on three proposals, each of which is described in more detail in the Company's definitive proxy statement filed with the U.S. Securities and Exchange Commission on March 26, 2024. The following is a brief description of each matter voted on and the certified results, including the number of votes cast for and against each matter, and if applicable, the number of abstentions and broker non-votes with respect to each matter. Proposal One – Three (3) nominees for election to the Board of Directors were elected to serve for a three-year term, and until their successors are duly elected and qualified, based upon the following votes: Director For Withheld Broker Non-Vote Remi Barbier 10,768,599 500,052 15,710,817 Sanford R. Robertson 8,944,665 2,323,986 15,710,817 Patrick J. Scannon, M.D., Ph.D. 10,891,367 377,284 15,710,817 Proposal Two – The appointment of Ernst & Young LLP as the independent registered public accounting firm for the Company for the fiscal year ending December 31, 2024, was ratified based upon the following votes: For Against Abstain 26,461,553 380,036 137,879 Proposal Three – The 2023 executive compensation for the Company's named executive officers was approved, on a non-binding advisory vote, based upon the following votes: For Against Abstain Broker Non -Vote 9,

View Full Filing

View this 8-K filing on SEC EDGAR

View on Read The Filing